visit website - infinzi

Infinzi is a global biotechnology company that focuses on the development and commercialization of innovative therapies aimed at improving the lives of patients with serious diseases. Primarily concentrated on oncology, Infinzi's mission is to harness the power of immunotherapy to address unmet medical needs, especially in cancer treatment.

Overview:

Infinzi, a subsidiary of AstraZeneca, is best known for its work in the field of cancer immunotherapy. The company is committed to advancing treatments that can help the immune system recognize and combat cancer more effectively. It specializes in the development of immune checkpoint inhibitors—a class of drugs that aim to boost the body’s natural immune response against tumors.

Key Areas of Focus:

1. Immuno-Oncology: Infinzi’s primary research focus is in immuno-oncology, which is an area of medicine that seeks to harness and enhance the body's immune system to fight cancer. Immunotherapies such as checkpoint inhibitors work by blocking certain proteins that prevent the immune system from attacking cancer cells.
2. Cancer Types: Infinzi’s treatments are primarily focused on treating solid tumors and various types of cancers such as lung cancer, bladder cancer, and head and neck cancers. The company has been involved in the development of therapies for both early-stage and advanced cancers.
3. Clinical Trials: As part of its commitment to discovering new treatments, Infinzi conducts clinical trials that test the efficacy and safety of its therapies. These trials often include combinations of Infinzi's therapies with other cancer treatments to explore synergistic effects.